Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Cyclophosphamide; Fludarabine; Mycophenolate mofetil; Tacrolimus
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 17 May 2017 Biomarkers information updated
- 13 Jul 2012 Planned number of patients changed from 70 to 50 as reported by ClinicalTrials.gov.
- 12 May 2011 Planned end date changed from 1 Jan 2009 to 1 Mar 2011 as reported by ClinicalTrials.gov.